Envue Medical Q1 FY26 net loss more than doubled to $3.82 million

ENvue Medical, Inc.

ENvue Medical, Inc.

FEED

0.00
  • Envue Medical posted a net loss that more than doubled to USD 3.82 million for the three months ended March 31, 2026.
  • Revenue fell 36% to USD 653, while gross margin swung to (11%) from 36% a year earlier.
  • Operating expenses climbed, with selling and marketing up more than doubled to USD 772 and general and administrative rising 80% to USD 2.42 million.
  • Cash used in operating activities widened to USD 4.31 million, leaving cash and cash equivalents at USD 2.24 million at quarter-end.
  • The company said it identified inaccuracies in its 510(k) application for PainShield MD Plus and asked the FDA to withdraw the clearance, intending to halt future sales of the product.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envue Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-024191), on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.